hyperCORE International, a strategic scaling platform that helps clinical research sites and organizations grow through partnership, announced the election of its officers on October 15, 2026. Jeffrey Smyth has been elected President, Seneca Harrison as Vice President, and Claxton Copeland as Secretary, while Dustin Owen will continue serving as Treasurer. The appointments signal a renewed focus on serving two distinct audiences through one platform: clinical research site networks and contract research organizations (CROs).
For site networks, hyperCORE accelerates growth while preserving independence. For CROs, it provides one strategic connection to a growing network of experienced, high-performing research sites. The new officers bring complementary expertise and strategic leadership to guide hyperCORE's continued evolution, strengthen partnerships, and support sustainable growth across the organization. This leadership transition is important because it positions hyperCORE to scale its collective impact at a time when clinical research demands efficient, reliable site access and site networks seek to expand without losing autonomy.
Newly elected President Jeffrey Smyth expressed gratitude for the confidence of his fellow partners. "The camaraderie across our network is what makes this group special, and it positions us well for continued growth," Smyth said. "I step into this role with excitement as we scale our collective impact for CROs and patients." His statement underscores the collaborative spirit that has driven hyperCORE's model, which relies on partnership rather than consolidation to achieve scale.
Nicholas Focil, former President, emphasized the organization's core purpose. "At hyperCORE, our purpose is simple. We help our partners scale," Focil said. "That means giving exceptional site networks the support to grow on their own terms, and giving CROs one trusted connection to the sites and patients their studies need. Strong leadership is essential to that mission, and we're pleased to welcome the new executive team." The election thus reinforces hyperCORE's dual value proposition: enabling site networks to expand their reach and build sustainable organizations, while offering CROs a single point of contact for rapid feasibility and broad geographic coverage.
hyperCORE's current class of partner site networks includes Empathx Clinical Research, FOMAT Medical Research, Optimal Research Sites, QCR Network, and TrueBlue Clinical Research. Its alumni include Lynd Clinical (formerly ARC), Avacare (formerly Benchmark Clinical Research), Flourish Research (formerly CSP & CTT), Centricity Research (formerly IACT Health, LMC Manna, Aventiv, and Lucas Research), and, most recently, Alcanza Clinical Research. This track record demonstrates the platform's ability to help networks grow and eventually transition to new stages, validating its scaling model.
For CROs, hyperCORE streamlines site access through a single point of contact. With one trusted relationship, CROs gain rapid feasibility with 48 to 72 hour turnaround, broader geographic reach across the United States, and expanded patient access. The network brings together more than 50 sites, 120+ principal investigators, and experience across more than 25 therapeutic areas and multiple trial phases, with access to more than 3.4 million patients. These metrics highlight the tangible benefits for CROs seeking efficient study startup and diverse patient populations.
The new officers will guide hyperCORE International as it continues to evolve. For more information about the platform and its partnership model, visit hyperCORE International. The leadership change is significant because it ensures continuity and fresh energy as hyperCORE pursues its mission to help partners scale, ultimately advancing clinical research and bringing therapies to patients faster.


